Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27161681 | 1.00 | ALDH1A1 (0.40) | ALDH1A1GAAKDM4ESMN1; SMN2LMNA | |
| SCHEMBL30049828 | 0.95 | ALDH1A1 (0.37) | ALDH1A1GAAKDM4ESMN1; SMN2LMNA | |
| SCHEMBL27161560 | 0.95 | ALDH1A1 (0.37) | ALDH1A1GAAKDM4ESMN1; SMN2LMNA | |
| SCHEMBL30049333 | 0.91 | ALDH1A1 (0.42) | ALDH1A1GAAKDM4ESMN1; SMN2LMNA | |
| SCHEMBL27161892 | 0.91 | ALDH1A1 (0.42) | ALDH1A1GAAKDM4ESMN1; SMN2LMNA | |
| SCHEMBL30051175 | 0.90 | TSHR (0.39) | ALDH1A1GAAKDM4ESMN1; SMN2LMNA | |
| SCHEMBL30049755 | 0.90 | CYP3A4 (0.41) | ALDH1A1GAAKDM4ESMN1; SMN2LMNA | |
| SCHEMBL27162570 | 0.90 | CYP3A4 (0.41) | ALDH1A1GAAKDM4ESMN1; SMN2LMNA | |
| SCHEMBL27161927 | 0.90 | TSHR (0.39) | ALDH1A1GAAKDM4ESMN1; SMN2LMNA | |
| SCHEMBL30049992 | 0.87 | ALDH1A1 (0.43) | ALDH1A1GAAKDM4ESMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4330248-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS | Acondicionamiento Tarrasense (ES) | 2024-03-06 | — | — | EP | claimed |
| WO-2022229405-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS | ACONDICIONAMIENTO TARRASENSE (ES) | 2022-11-03 | — | — | WO | claimed |
| US-20240254115-A1 | New Pyridine-Sulfonamide Derivatives as Sigma Ligands | ACONDICIONAMIENTO TARRASENSE (ES) | 2024-08-01 | — | — | US | disclosed |
| EP-4330248-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS | Acondicionamiento Tarrasense (ES) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022229405-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS | ACONDICIONAMIENTO TARRASENSE (ES) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254115-A1 | New Pyridine-Sulfonamide Derivatives as Sigma Ligands | SIGMAR1, TMEM97, OPRD1 | ALDH1A1 1011/4885GAA 3700/4885KDM4E 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.